Is Bristol-Myers Squibb Company (BMY) the Best Wide Moat Stock to Invest In?
We recently published a list of 10 Best Wide Moat Stocks to Invest In. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other best wide moat stocks to invest in.
Bristol-Myers Squibb, Amazon And 3 Stocks To Watch Heading Into Thursday
With U.S. stock futures trading higher this morning on Thursday, some of the stocks that may grab investor focus today are as follows:
Bristol Myers Squibb call volume above normal and directionally bullish
Bullish option flow detected in Bristol Myers ( BMY) Squibb with 17,611 calls trading, 2.0x expected, and implied vol increasing over 1 point to 29.73%. May-25 67.5 calls and Aug-25 45 puts are the most active options, with total volume in those strikes near 9,400 contracts. The Put/Call Ratio is 0.61. Earnings are expected on February 6th.
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors
Bristol Myers Squibb Co. closed 3.24% short of its 52-week high of $61.10, which the company reached on January 27th.
Bristol-Myers Squibb (BMY) to Release Earnings on Thursday
Bristol-Myers Squibb (NYSE:BMY – Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Thursday, February 6th. Analysts expect the company to announce earnings of $1.
Jefferies Keeps Their Buy Rating on Bristol-Myers Squibb (BMY)
Jefferies analyst Akash Tewari maintained a Buy rating on Bristol-Myers Squibb (BMY – Research Report) on February 3 and set a price target of
Bristol-Myers Squibb's SWOT analysis: stock outlook mixed amid pipeline progress
Bristol-Myers Squibb (NYSE:BMY), a global biopharmaceutical giant with a market capitalization of $120.8 billion, finds itself at a critical juncture as it navigates a complex landscape of opportunities and challenges.
Bristol-Myers Squibb Q4 2024 Earnings Preview: Strong product sales to continue into 2025
Bristol-Myers Squibb Company  (NYSE:BMY) is scheduled to announce Q4 earnings results on Thursday, February 6th, before ...
Earnings To Watch: Bristol-Myers Squibb (BMY) Reports Q4 Results Tomorrow
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be reporting results tomorrow before the bell. Here’s what you ...
Research Analysts Issue Forecasts for BMY FY2024 Earnings
Analysts at Cantor Fitzgerald increased their FY2024 earnings estimates for shares of Bristol-Myers Squibb in a research note issued to investors on Tuesday, February 4th. Cantor Fitzgerald analyst O.
FiercePharma1d
Bristol Myers Squibb, Kyowa Kirin layoffs hit 119 in New Jersey amid separate restructuring campaigns
As the major cost-cutting initiative at Bristol Myers Squibb rolls on, the company has launched another round of layoffs in ...
Bristol-Myers Squibb: Too Valuable Not To Hold This Pharma Gem, But Debt Challenges Remain
Bristol-Myers Squibb gets rated a hold, as I see future value in its clinical portfolio and pipeline, particularly ...
2 High-Yield Dividend Stocks to Hold Through 2025 and Beyond
Such companies can be wonderful options for income-seeking investments. If you're in the market for that combo, let's ...
FiercePharma11d
Bristol Myers, Pfizer tout new standards of care in colorectal cancer subtypes
Old drugs from Bristol Myers Squibb and Pfizer have delivered what the companies and researchers believe could establish them ...
Cantor Fitzgerald lifts Bristol-Myers price target to $55
Cantor Fitzgerald updated its financial model for Bristol-Myers Squibb Co. (NYSE:BMY), leading to an increased price target on the company's stock. Analysts at the firm now see the price target at $55 ...